How should I evaluate and manage a 17-year-old with a newly onset rapid heart rate?

Immediate Assessment and Management of New-Onset Rapid Heart Rate in a 17-Year-Old

In a 17-year-old with new-onset rapid heart rate, immediately assess hemodynamic stability and obtain a 12-lead ECG to determine if this is a narrow-complex or wide-complex tachycardia, as this distinction drives all subsequent management decisions.

Initial Stabilization and Assessment

First, determine if the patient is stable or unstable 1. Unstable signs include:

• Acute altered mental status
• Ischemic chest pain
• Acute heart failure symptoms
• Hypotension or shock
• Syncope

While assessing stability:

• Provide supplemental oxygen if needed
• Attach continuous cardiac monitoring
• Establish IV access
• Obtain a 12-lead ECG (don't delay treatment if unstable)
• Check vital signs including blood pressure and oxygen saturation 1

Critical decision point: If the heart rate is >150 bpm with hemodynamic compromise, prepare for immediate synchronized cardioversion 1, 2. If heart rate is <150 bpm, the tachycardia is more likely secondary to an underlying condition rather than the primary problem 1.

ECG Analysis: Narrow vs. Wide Complex

Narrow-Complex Tachycardia (QRS <0.12 seconds)

The most common causes in adolescents are 3:

• Supraventricular tachycardia (SVT) - most likely in this age group, typically AVNRT or AVRT
• Sinus tachycardia (look for gradual onset/offset, identifiable P waves)
• Atrial fibrillation (irregular rhythm)

For stable narrow-complex SVT 1, 2:

1. Try vagal maneuvers first (unless causing undue delay):

   • Ice to face in younger patients
   • Valsalva maneuver (blow through narrow straw) in older adolescents
   • These work in 20-30% of cases 4

2. Adenosine is first-line pharmacologic therapy 1, 2, 4:

   • 6 mg rapid IV push, followed immediately by saline flush
   • If no response: 12 mg rapid IV push
   • Success rate >90% for AVNRT/AVRT 5
   • Warn patient about transient chest discomfort, flushing, sense of dread 2
   • Contraindicated in asthma (can cause severe bronchospasm) 2

3. Alternative agents if adenosine fails or unavailable:

   • IV diltiazem or verapamil (64-98% conversion rate) 2
   • Avoid calcium channel blockers if heart failure suspected 2
   • IV beta-blockers are safe alternatives 2

Wide-Complex Tachycardia (QRS ≥0.12 seconds)

Assume ventricular tachycardia until proven otherwise 1. In an unstable patient, proceed immediately to synchronized cardioversion 1.

For stable wide-complex tachycardia 1:

• Obtain expert consultation immediately
• If regular and monomorphic, IV adenosine is relatively safe for both diagnosis and treatment (Class IIb) 1
• Do NOT give adenosine if irregular or polymorphic 1
• Consider amiodarone 150 mg IV over 10 minutes if VT suspected 1

Critical Pitfalls to Avoid

Pre-excitation/Wolff-Parkinson-White Syndrome 6:

• If baseline ECG shows delta waves or you suspect WPW with atrial fibrillation:
  • NEVER give AV nodal blockers (adenosine, diltiazem, verapamil, digoxin, beta-blockers) 6
  • These can paradoxically accelerate ventricular rate and cause hemodynamic collapse 6
  • Use procainamide or ibutilide instead 6
  • Immediate cardioversion if hemodynamically unstable 6

Sequential AV nodal blockers:

• Don't give calcium channel blockers or beta-blockers after adenosine without adequate time interval
• Overlapping effects can cause profound bradycardia 1

Disposition and Follow-Up

All adolescents with documented SVT require 3, 4, 7:

• Referral to pediatric cardiology or electrophysiology
• Echocardiogram to exclude structural heart disease 3
• Consider Holter or event monitor if rhythm not captured 3, 7

Indications for immediate cardiology consultation 3, 7:

• Wide-complex tachycardia of unknown origin
• Syncope associated with palpitations
• Abnormal baseline ECG (pre-excitation, prolonged QT)
• Family history of sudden cardiac death or inherited arrhythmia syndromes
• Palpitations triggered by exercise

Long-Term Management Considerations

For recurrent SVT in adolescents 5, 8, 9:

• Catheter ablation has become first-line therapy in older children/adolescents
  • 95% success rate, <5% recurrence, <1% risk of heart block 5
  • Preferred over chronic antiarrhythmic therapy 8
• Prophylactic medications (if ablation declined or not candidate):
  • Beta-blockers or calcium channel blockers for rate control
  • Class IC agents (flecainide, propafenone) for rhythm control
  • Avoid Class Ia and III agents due to adverse effects unless specialist-directed 5

Key point: Unlike infants where SVT often resolves spontaneously in the first year, spontaneous resolution in adolescents is rare 9, making definitive therapy more important in this age group.